Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 5/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PTPRF | P10586 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500047 | 1.00 | PTPRB (0.50) | PTPRBROCK1NPC1RAB9ACCR3 | |
| SCHEMBL23303479 | 0.88 | PTPRB (0.51) | PTPRBNPC1RAB9ACCR3KDM4E | |
| SCHEMBL23303481 | 0.88 | PTPRB (0.51) | PTPRBNPC1RAB9ACCR3KDM4E | |
| SCHEMBL29794295 | 0.85 | PTPRB (0.50) | PTPRBNPC1RAB9ACCR3KDM4E | |
| SCHEMBL27240710 | 0.85 | PTPRB (0.61) | PTPRBCCR3 | |
| SCHEMBL16030968 | 0.85 | PTPRB (0.61) | PTPRBCCR3 | |
| SCHEMBL27240709 | 0.85 | PTPRB (0.61) | PTPRBCCR3 | |
| SCHEMBL16030965 | 0.85 | PTPRB (0.61) | PTPRBCCR3 | |
| SCHEMBL468068 | 0.84 | KDM4E (0.43) | ROCK1NPC1RAB9AKDM4ELMNA | |
| SCHEMBL23303494 | 0.84 | PTPRB (0.59) | PTPRBNPC1RAB9ACCR3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114939117-A | Method of treating vascular leak syndrome | 视点制药公司 | 2022-08-26 | — | — | CN | disclosed |
| EP-2967066-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Therapeutics Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014145068-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | AERPIO THERAPEUTICS INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2451279-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | Akebia Therapeutics Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| EP-2385763-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | Akebia Therapeutics Inc. (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110253725-A1 | MULTI-PORT BEVERAGE AND FOOD CONTAINERS | KILLIAN WILLIAM | 2011-10-20 | — | — | US | disclosed |
| WO-2011005330-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AKEBIA THERAPEUTICS INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010081172-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AKEBIA THERAPEUTICS INC. (US) | 2010-07-15 | — | — | WO | disclosed |